newsfilter
← Latest News
Business Wire·

Aptinyx Reports Results from Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies and Provides Pipeline and Corporate Update

NYX-458 did not demonstrate sufficient efficacy in the Phase 2 study to support further development by Aptinyx The company will undertake cost-cutting measures and explore strategic alternatives The company will